Vanguard Global Advisers
RNAC icon

Vanguard Global Advisers’s Cartesian Therapeutics RNAC Stock Holding History

Vanguard Global Advisers’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.8K Hold
3,630
– – ﹤0.01% 3158
2026
Q1 		$22.3K Buy
+3,630
New +$25.9K ﹤0.01% 3272

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's RNAC Position: Q2 2026 in Review

Vanguard Global Advisers held its Cartesian Therapeutics (RNAC) position steady in Q2 2026 at 3,630 shares worth $37.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3158.

Vanguard Global Advisers first reported a position in RNAC in Q1 2026 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Vanguard Global Advisers held 3,630 shares of Cartesian Therapeutics worth $37.8K as of Q2 2026.
  • Vanguard Global Advisers left its Cartesian Therapeutics share count unchanged in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3158 holding.
  • Vanguard Global Advisers first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.